Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
Yeah Baby: Virtus Health On A Growth Path
May 14 2014
Brokers consider Virtus Health has good growth potential, supported by changing demographics.
Weekly Broker Wrap: The Aussie, Wesfarmers, Pharma Stocks And The Genworth IPO
May 09 2014
AUD strength; Wesfarmers versus Woolworths; pharmaceutical stocks evaluated; Genworth plans Oz IPO.
Brokers Warm To ResMed As Price Disruptions Abate
Apr 28 2014
Following the March quarter update many brokers believe ResMed is now well placed for improved earnings growth.
Your Editor On Switzer: Healthcare Stocks Defensive?
Apr 28 2014
The FNArena Editor explains why investors too easily assume that healthcare stocks are a safe haven in Australia.
QRxPharma Knocked Back And Knocked Down
Apr 28 2014
Drug developer QRxPharma has been set back by the US FDA advisory committee’s rejection of MoxDuo-IR.
What’s Likely In The Federal Budget For Health Care?
Apr 23 2014
Brokers mull the potential health care changes and impact on stocks from the upcoming federal budget.
ResMed Pullback Complete
Apr 22 2014
Michael Gable of Fairmont Equities suggests the upside trend for ResMed may shortly resume.
CSL Needs To Reinvigorate Broker Appetite
Apr 15 2014
Several brokers have looked at CSL in recent days and decided the stock is getting somewhat expensive.
Recapturing Market Share The Key For Cochlear
Mar 25 2014
The US FDA has approved Cochlear’s Nucleus Hybrid L24. It’s a welcome development but brokers remain focused on the challenges ahead.
Ansell’s Upward Trend
Mar 06 2014
The Chartist suggests recent weakness in Ansell does not undermine a strong longer term trend.
Analyse The Market From A Different Angle
Latest News
| 1 |
Today’s Financial Calendar – 24-01-20258:15 AM - Daily Market Reports |
| 2 |
ASX Winners And Losers Of Today – 23-01-25Jan 23 2025 - Daily Market Reports |
| 3 |
Rudi’s View: Feb Season’s Best Buys & Key PicksJan 23 2025 - Rudi's View |
| 4 |
Australian Broker Call *Extra* Edition – Jan 23, 2025Jan 23 2025 - Daily Market Reports |
| 5 |
Xero: The Pause That RefreshesJan 23 2025 - Technicals |